Michael Okaty Discusses the State of M&A and Due Diligence Implications of the Russia-Ukraine War
01 April 2022
WSJ CFO Journal
Foley & Lardner LLP Partner Michael Okaty was featured in the WSJ CFO Journal article, “Some Companies Put M&A on Hold Amid Russian War on Ukraine,” discussing how companies are pulling back, delaying, or taking additional time to analyze potential deals because of the conflict.
Okaty states that deals at this time, “require heightened diligence” including assessments of whether operations can continue if employees need to be transported, or if the work can be done elsewhere.
(Subscription required)
As the Russia-Ukraine war continues, so too do new business and legal implications for companies around the world. For more information on how to mitigate risk and protect your business, contact a Foley lawyer today.
People
Related News
26 September 2024
In the News
Gregory Marino on NIL Litigation – 'Schools want to know where the line is, and now everything is in flux'
Foley & Lardner LLP special counsel Gregory Marino shared insight on the growing complexities of collegiate sports in the ABA Journal article, "Money and litigation tangle with recent rules for college athletes' NIL deals."
24 September 2024
In the News
Thomas Ferrante Assesses Recent HHS OIG Report on Remote Patient Monitoring
Foley & Lardner LLP partner Thomas Ferrante commented on the recently released report on remote patient monitoring from the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Fierce Healthcare article, “HHS watchdog flags potential remote monitoring fraud. Stakeholders say concerns about misuse are overblown.”
20 September 2024
In the News
David Rosen Featured for Insight on Looming FDA Final Rule for Cosmetic Manufacturing
Foley & Lardner LLP partner David Rosen is featured by CosmeticsDesign for his insights on the U.S. Food and Drug Administration's final rule establishing Good Manufacturing Practices for the cosmetics industry in the article, "Preparing for MoCRA’s 2025 cGMP deadline: What cosmetic manufacturers and suppliers need to know."